Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN), 'reiterate URGN as a top pick'

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $40.00 price target on UroGen Pharma (NASDAQ: URGN).

The analyst commented: "Urogen announced that the FDA has accepted UGN-102's new drug application (NDA) for review and has assigned an action date of June 13, 2025. We continue to anticipate approval for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and see '102 achieving $1B+ US sales over time. We await clarity on a potential ad comm, which we do not regard as a source of concern given 102's strong efficacy/safety package. We would take advantage of any share weakness today which we would attribute to the lack of Priority Review (would have put potential approval in February). We reiterate URGN as a top pick."

For an analyst ratings summary and ratings history on UroGen Pharma click here. For more ratings news on UroGen Pharma click here.

Shares of UroGen Pharma closed at $12.26 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• DA Davidson Reiterates Neutral Rating on Timken (TKR)
• DA Davidson Reiterates Buy Rating on Dynatrace Inc. (DT) on Agreement to Acquire Arize